Literature DB >> 15868771

Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters.

Seung Ha Park1, Woo Kyu Jeon, Sang Hoon Kim, Hong Joo Kim, Dong Il Park, Yong Kyun Cho, In Kyung Sung, Chong Il Sohn, Byung Ik Kim, Dong Keuk Keum.   

Abstract

BACKGROUND: An increased risk in coronary heart disease associated with Helicobacter pylori (H. pylon) appears to be partially mediated by modifications of the atherogenic lipoprotein and inflammatory parameters. We conducted a controlled trial aimed at evaluating the changes of metabolic and inflammatory parameters after H. pylon eradication.
METHODS: We included in the study 169 patients with H. pylori infection and conducted a retrospective longitudinal survey of 87 subjects (76 men, 11 women) who received treatment for H. pylon eradication and 82 control subjects (63 men, 19 women) who did not receive treatment. We compared pre- and posteradication (one year after) the metabolic and inflammatory parameters, such as blood sugar, lipid profiles, insulin resistance, white blood cell count and C-reactive protein.
RESULTS: No significant changes from the baseline in metabolic and inflammatory parameters within each group were observed. Changes in the serum levels of metabolic and inflammatory parameters were similar between the two groups.
CONCLUSIONS: Metabolic and inflammatory parameters, including blood sugar, lipid profiles, insulin resistance, white blood cell count and C-reactive protein, were not changed after H. pylori eradication treatment. H. pylori eradication has no effect on metabolic and inflammatory parameters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868771      PMCID: PMC2568737     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  15 in total

1.  Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies.

Authors:  J Danesh; R Peto
Journal:  BMJ       Date:  1998-04-11

2.  Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease.

Authors:  J Regnström; S Jovinge; P Båvenholm; C G Ericsson; U De Faire; A Hamsten; M L Hellenius; J Nilsson; P Tornvall
Journal:  J Intern Med       Date:  1998-02       Impact factor: 8.989

3.  Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile.

Authors:  A Hoffmeister; D Rothenbacher; G Bode; K Persson; W März; M A Nauck; H Brenner; V Hombach; W Koenig
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

4.  Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death.

Authors:  Jianhui Zhu; Arshed A Quyyumi; Joseph B Muhlestein; F Javier Nieto; Benjamin D Horne; Alexandra Zalles-Ganley; Jeffrey L Anderson; Stephen E Epstein
Journal:  Am J Cardiol       Date:  2002-01-15       Impact factor: 2.778

5.  Effect of Helicobacter pylori infection and its eradication on nutrition.

Authors:  T Furuta; N Shirai; F Xiao; M Takashima; H Hanai
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

6.  Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease.

Authors:  M A Mendall; P Patel; M Asante; L Ballam; J Morris; D P Strachan; A J Camm; T C Northfield
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

7.  Helicobacter pylori CagA seropositivity does not influence inflammatory parameters, lipid concentrations and haemostatic factors in healthy individuals.

Authors:  F Parente; V Imbesi; C Cucino; G MacOni; U Russo; P G Duca; G Bianchi Porro
Journal:  J Intern Med       Date:  2000-02       Impact factor: 8.989

8.  Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).

Authors:  Adam F M Stone; Michael A Mendall; Juan-Carlos Kaski; Tracey M Edger; Paul Risley; Jan Poloniecki; A John Camm; Timothy C Northfield
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

9.  Plasma ghrelin following cure of Helicobacter pylori.

Authors:  C U Nwokolo; D A Freshwater; P O'Hare; H S Randeva
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol.

Authors:  Hubert Scharnagl; Manfred Kist; Andrea Busse Grawitz; Wolfgang Koenig; Heinrich Wieland; Winfried März
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

View more
  17 in total

Review 1.  Role of Helicobacter pylori infection in pathogenesis of atherosclerosis.

Authors:  Rajesh Vijayvergiya; Ramalingam Vadivelu
Journal:  World J Cardiol       Date:  2015-03-26

Review 2.  Role of Helicobacter pylori infection on nutrition and metabolism.

Authors:  Francesco Franceschi; Tortora Annalisa; Di Rienzo Teresa; D'Angelo Giovanna; Gianluca Ianiro; Scaldaferri Franco; Gerardi Viviana; Tesori Valentina; Lopetuso Loris Riccardo; Gasbarrini Antonio
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Helicobacter pylori infection and diabetes: is it a myth or fact?

Authors:  Cong He; Zhen Yang; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Insulin resistance in H pylori infection and its association with oxidative stress.

Authors:  Mehmet Aslan; Mehmet Horoz; Yasar Nazligul; Cengiz Bolukbas; F Fusun Bolukbas; Sahbettin Selek; Hakim Celik; Ozcan Erel
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

5.  Association between helicobacter pylori infection and body mass index, before and after eradication of infection in hemodialysis batients.

Authors:  Mojgan Jalalzadeh; Mohammad Hassan Ghadiani; Nouraddin Mousavinasab
Journal:  J Nephropathol       Date:  2012-10-01

6.  Comparison of azithromycin and clarithromycin triple therapy regimens for helicobacter pylori eradication in hemodialysis patients.

Authors:  Mojgan Jalalzadeh; Morteza Nazarian; Jamshid Vafaeimanesh; Fatemeh Mirzamohammadi
Journal:  Nephrourol Mon       Date:  2012-06-20

7.  Helicobacter pylori infection as a risk factor for insulin resistance.

Authors:  Ahad Eshraghian; Seyed Ali Hashemi; Alireza Hamidian Jahromi; Hamed Eshraghian; Seyed Masoum Masoompour; Mohamad Ali Davarpanah; Kavus Eshraghian; Seyed Alireza Taghavi
Journal:  Dig Dis Sci       Date:  2008-11-14       Impact factor: 3.199

8.  The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos Zavos; Georgia Deretzi
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  The Role of Helicobacter pylori Seropositivity in Insulin Sensitivity, Beta Cell Function, and Abnormal Glucose Tolerance.

Authors:  Lou Rose Malamug; Rudruidee Karnchanasorn; Raynald Samoa; Ken C Chiu
Journal:  Scientifica (Cairo)       Date:  2014-03-25

10.  A comparative study of broccoli sprouts powder and standard triple therapy on cardiovascular risk factors following H.pylori eradication: a randomized clinical trial in patients with type 2 diabetes.

Authors:  Parvin Mirmiran; Zahra Bahadoran; Mahdieh Golzarand; Homayoun Zojaji; Fereidoun Azizi
Journal:  J Diabetes Metab Disord       Date:  2014-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.